瑞典强直性脊柱炎、其他脊柱关节炎及银屑病关节炎患者中的结核风险:一项基于人群的队列研究
在瑞典全国登记库中纳入38702例强直性脊柱炎/脊柱关节炎/银屑病关节炎患者和200417名一般人群对照,随访活动性结核发生。生物制剂初治患者较一般人群的调整HR为1.2(95%CI 0.5-2.7),生物制剂暴露者较初治者的调整HR为7.5(95%CI 1.9-29)。作者结论为生物制剂初治患者结核风险未增加,生物制剂治疗后风险升高但绝对风险低。
要点
- 生物制剂初治的AS/SpA/PsA患者结核风险与一般人群无显著差异(调整HR 1.2,95%CI 0.5-2.7)。
- 生物制剂暴露患者结核风险高于初治患者(调整HR 7.5,95%CI 1.9-29)。
- 生物制剂暴露患者结核发病率22/10^5(95%CI 8.3-59.2),绝对风险低。
核心结论
- 在瑞典,生物制剂初治的AS/SpA/PsA患者结核风险未增加,生物制剂治疗后风险升高但绝对结核风险低。
研究设计与样本
- 基于瑞典全国患者、人口、结核和风湿病登记库链接的基于人群的队列研究,纳入38702例AS/SpA/PsA患者和200417名非AS/SpA/PsA一般人群对照,随访结核发生。
主要发现
- 共识别11例活动性结核病例。
- 生物制剂暴露患者结核发病率为22/10^5(95%CI 8.3-59.2)。
- 生物制剂初治患者结核发病率为2.7/10^5(95%CI 1.3-5.6)。
- 非AS/SpA/PsA对照结核发病率为2.4/10^5(95%CI 1.8-3.3)。
- 生物制剂初治患者较一般人群的调整HR为1.2(95%CI 0.5-2.7),生物制剂暴露者较初治者的调整HR为7.5(95%CI 1.9-29)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Rheumatoid arthritis is a risk factor for tuberculosis (TB), particularly following treatment with biologic agents. Since these therapies are increasingly used in ankylosing spondylitis (AS), other types of spondyloarthritis (SpA), and psoriatic arthritis (PsA), we investigated the corresponding TB risks in these patients. METHODS: We identified individuals with AS/SpA/PsA, and non-AS/SpA/PsA comparators by linking Swedish national patient, population, TB, and rheumatology registers, and followed them for TB occurrence. Incidence rates were estimated for biologic-naive and biologic-exposed patients and the comparators. We calculated hazard ratios (HRs), adjusted for age, sex, and country of birth. RESULTS: Included in this study were 38,702 patients with AS/SpA/PsA, and 200,417 persons from the general population. Among the patients, 11 active TB cases were identified, with an incidence rate (per 105 ) of 22 (95% confidence interval [95% CI] 8.3-59.2) for biologic-exposed patients, 2.7 (95% CI 1.3-5.6) for biologic-naive patients, and 2.4 (95% CI 1.8-3.3) for non-AS/SpA/PsA comparators. The adjusted HR comparing biologic-naive patients to the general population was 1.2 (95% CI 0.5-2.7), and 7.5 (95% CI 1.9-29) comparing biologic-exposed to biologic-naive patients. CONCLUSION: Biologic-naive AS/SpA/PsA patients are not at an increased TB risk in Sweden. Following treatment with biologic agents, the risk increased, but the absolute TB risk was low.
引用
- de Vries MK, Arkema EV, Jonsson J, et al. Tuberculosis Risk in Ankylosing Spondylitis, Other Spondyloarthritis, and Psoriatic Arthritis in Sweden: A Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2018. PMID: 29195024. doi:10.1002/acr.23487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。